argenx SE (ARGX) and ObsEva SA (NASDAQ:OBSV) Comparing side by side

argenx SE (NASDAQ:ARGX) and ObsEva SA (NASDAQ:OBSV) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
argenx SE 157 0.00 36.88M -1.73 0.00
ObsEva SA 4 0.00 11.72M -2.48 0.00

Demonstrates argenx SE and ObsEva SA earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 has argenx SE and ObsEva SA’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
argenx SE 23,524,909.10% 0% 0%
ObsEva SA 313,268,470.01% -99.3% -75.7%

Analyst Ratings

The next table highlights the delivered recommendations and ratings for argenx SE and ObsEva SA.

Sell Ratings Hold Ratings Buy Ratings Rating Score
argenx SE 0 2 5 2.71
ObsEva SA 0 1 2 2.67

$177.57 is argenx SE’s average target price while its potential upside is 16.36%. On the other hand, ObsEva SA’s potential upside is 470.65% and its average target price is $21. The data provided earlier shows that ObsEva SA appears more favorable than argenx SE, based on analyst opinion.

Insider & Institutional Ownership

argenx SE and ObsEva SA has shares held by institutional investors as follows: 55.81% and 74%. Competitively, ObsEva SA has 14.47% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
argenx SE -0.43% 16.86% 14.28% 22.55% 42.3% 53.45%
ObsEva SA 0.44% -42.48% -51.07% -59.66% -68.74% -63.9%

For the past year argenx SE has 53.45% stronger performance while ObsEva SA has -63.9% weaker performance.

Summary

argenx SE beats ObsEva SA on 7 of the 11 factors.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. The company intends to develop products for treating endometriosis, uterine fibroids, and preterm labor, as well as for enhancing clinical pregnancy and live birth rates in women undergoing IVF. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to improve clinical pregnancy and live birth rates in women undergoing IVF; and OBE022, an oral and selective prostaglandin F2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of pregnancy. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.